Business Context and Reporting Period
This Form 8-K filing by Calidi Biotherapeutics, Inc. (CLDI) covers events occurring on June 17, 2026, and June 23, 2026. The report details corporate governance changes, specifically the appointment of a new director and adjustments to the Board of Directors' composition and committee assignments.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and personnel changes rather than financial performance.
Material Changes
- Board Expansion: The Board size increased from five (5) to six (6) members.
- New Director Appointment: Dr. Corazon (Corsee) Sanders was appointed as a Class III director, with a term expiring at the 2029 annual meeting.
- Committee Assignments: Dr. Sanders was appointed to the Audit Committee. Concurrently, Scott Leftwich was removed from the Audit Committee, though he remains a Board member.
- Compensation Deferral: The initial equity award for Dr. Sanders was deferred pending Board assessment of available awards under the 2023 Equity Incentive Plan.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or discussion of material risks and contingencies. Management commentary is limited to the rationale for Dr. Sanders' appointment, citing her over 30 years of global leadership experience in drug development and regulatory approval at companies such as Genentech/Roche and Juno Therapeutics.
Investor Verification Checklist
- Verify the effective date of Dr. Sanders' Audit Committee membership (June 17, 2026).
- Confirm the status of the deferred equity award for Dr. Sanders and the timeline for its grant.
- Review the updated Board composition to confirm the total number of directors is now six.
- Check subsequent filings for the specific number of shares allocated to Dr. Sanders once the Board completes its assessment.